Upload
buituyen
View
216
Download
4
Embed Size (px)
Citation preview
Abstract Title Author List Session
ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human phase I study
J Bendell, M Patel, J Infante, C Kurkjian, S Jones, S Pant, H Burris, J Hainsworth, O Moreno, K Moore
October 20 12:30-3:00pm A17 Poster Session A: Apoptosis, Necrosis, and Autophagy
Exhibit Hall C-DActivity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR+) breast cancer cell lines and patients (pts) with genetically characterized HR+ breast cancer in a Phase I clinical trial
M M Mita, HT Arkenau, JC Bendell, PN Munster, A Mahipal, J P Delord, LG Paz-Ares, JC Soria, S Xu, T Tran, T Shi, X Wu, R Chopra, K Hege, A Varga
October 20 12:30-3:00pm A68 Poster Session A: Clinical Trials
Exhibit Hall C-D
Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer
M Patel, J Infante, KN Moore, M Keegan, A Poli, M Padval, SF Jones, J Horobin, HA Burris III
October 20 12:30-3:00pm A69 Poster Session A: Clinical Trials
Exhibit Hall C-DA Phase Ib study of CC-486 (Oral Azacitidine) as a priming agent for carboplatin or NAB-paclitaxel in subjects with relapsed and refractory solid tumors
P LoRusso, D Rasco, J Bendell, J Sachdev, R Ramanathan, G Weiss, P Munster, WJ Edenfield, K Liu, A Blackwood-Chirchir, J DiMartino, DD Von Hoff
October 20 12:30-3:00pmA120 Poster Session A: Epigenetic Targets
Exhibit Hall C-DA phase 1 pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily (BID) in patients (pts) with advanced solid tumors
J Bendell, C Kurkjian, J Infante, T Bauer, HA Burris III, D Spigel, D Yardley, F Greco, K Shih, D Thompson, S Jones
October 20 12:30-3:00pmA166 Poster Session A: mTOR/PI3-Kinase
Exhibit Hall C-D
Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors
G Shapiro, R Kristeleit, M Middleton, HA Burris III, L Rhoda Molife, J Evans, R Wilson, P LoRusso, J Spicer, V Dieras, M Patel, E Dominy, D Simpson, H Giordano, AR Allen, SS Jaw-Tsai, R Plummer
October 20 12:30-3:00pmA218 Poster Session A: Pharmacokinetics and
Pharmacodynamics Exhibit Hall C-D
A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers
JC Bendell, AW Tolcher, SF Jones, M Beeram, JR Infante, P Larsen, K Rasor, JE Garrus, J Li, PL Cable, C Eberhardt, J Schreiber, S Rush, KW Wood, E Barrett, A Patnaik
October 20 12:30-3:00pmA252 Poster Session A: Therapeutic Agents: Biological
Exhibit Hall C-DPhase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas
JR Infante, G Shapiro, P Witteveen, J Gerecitano, V Ribrag, R Chugh, A Chakraborty, A Matano, X Zhao, S Parasuraman, PA Cassier
October 20 12:30-7:30pmA276 Therapeutic Agents: Small Molecule Kinase Inhibitors
Exhibit Hall C-D
Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686
J Sun, C Karlovich, W Wen, H Wakelee, S Chien, E Mann, P O’Donnell, P Angenendt, R Dziadziuszko, L Horn, DR Spigel, L Sequist, J Soria, B Solomon, DR Camidge, J Goldman, SM Gadgeel, M Raponi, L Wu, K Park
October 21 12:30-3:00pmB25 Poster Session B: Biomarkers
Exhibit Hall C-D
A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors
A El-Khoueiry, C Kurkjian, T Semrad, L Musib, M Gates, S Eppler, I Chang, I Chan, I Rooney, J Bendell
October 21 12:30-3:00pmB75 Poster Session B: Clinical Trials
Exhibit Hall C-DA Phase I study of CC-486 (oral azacitidine) to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of azacitidine administered alone and in combination with carboplatin or ABI-007 (NAB-paclitaxel) in subjects with solid tumors
E Laille, AN Nguyen, G Chen, D Rasco, P LoRusso, DD Von Hoff, J Bendell, P Munster, WJ Edenfield, R Ramanathan, MB Gonzalez, A Blackwood-Chichir, J DiMartino
October 21 12:30-3:00pmB217 Poster Session B: Pharmacokinetics and
PharmacodynamicsExhibit Hall C-D
Drug-drug interaction assessment of GDC-0032, a beta-sparing inhibitor of phosphoinositide 3-kinase (PI3K), using midazolam, a sensitive CYP3A4 substrate
RA Graham, S Cheeti, L Salphati, T Lu, C Kurkjian, DV Hoff, J Sachdev, D Juric, J Baselga, H Parmer, J Hsu, JR Infante
October 21 12:30-3:00pmB218 Poster Session B: Pharmacokinetics and
PharmacodynamicsExhibit Hall C-D
A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies
JR Infante, J Tabernero, A Cervantes, S Jalal, HA Burris III, T Macarul-la, A Perez-Fidalgo, R Neuwirth, C Patel, E Gangolli, R Brake, J Sturm, EH Westin, M Gordon
October 21 12:30-3:00pmC252 Poster Session C: Therapeutic Agents: Small Molecule
Kinase InhibitorsExhibit Hall C-D
SM
AACR-NCI-EORTC International Conference onMolecular Targets and Cancer Therapeutics
October 19-23, 2013Hynes Convention Center
Boston, MA, USA
Sarah Cannon Research Institute has 13 abstracts accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
SCRI Lead Author SCRI Co-Author
About the Conference: Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2013 Molecular Targets and Cancer Therapeutics conference will bring together an estimated 3,000 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
The following SCRI Principal Investigators have abstracts accepted for presentation:
SMAACR-NCI-EORTC International Conference on
Molecular Targets and Cancer TherapeuticsOctober 19-23, 2013
Hynes Convention CenterBoston, MA, USA
Howard A. “Skip” Burris, III, M.D. Chief Medical Officer Executive Director, Drug Development Program
John D. Hainsworth, M.D.Chief Scientific Officer
F. Anthony Greco, M.D.Director of Sarah Cannon Cancer Center
Jeffrey R. Infante, M.D.Director, Drug Development Program
Johanna C. Bendell, M.D.Director of GI Cancer Research ProgramAssociate Director, Drug Development
Denise A. Yardley, M.D.Senior Investigator, Breast Cancer Research Program
Kent Shih, M.D.Senior Investigator, Neuro-Oncology Program
Todd Bauer, M.D.Investigator, Drug Development
Suzanne Jones, Pharm.D.Scientific Director, Drug Development Program
Hendrik-Tobias Arkenau, M.D., Ph.DDirector, Drug Development Program Sarah Cannon Research UK
Other SCRI-affilliated investigators presenting at the meeting are:
Manish R. Patel, MDDana S. Thompson, MD